BB Biotech Ag Approves Dividend, Payable on March 25, 2020; Announces Board Changes
The company also announced that Prof. Dr. Dr. Klaus Strein announced last year that he was stepping down from the Board and there did not stand for re-election. The Board of Directors thanks Klaus Strein for his valuable contribution and personal commitment to BB Biotech over the past seven years
The company also announced that two new directors were elected - Prof. Dr. Mads Krogsgaard Thomsen and, with effect from October 1, 2020, Dr. Susan Galbraith. Susan Galbraith joined AstraZeneca in 2010 and heads its Oncology Research and Early Development Department. She oversaw the successful development of several cancer drugs that have been approved worldwide. Mads Krogsgaard currently serves as Executive Vice President and Chief Science Officer with responsibility for global drug and device research, CMC and global drug development, regulatory affairs and drug safety.